Dawn D Smiley, MD, MS
Adjunct Associate Professor of Medicine
Department of Medicine
Dr. Dawn Smiley graduated from Fisk University with a B.A. in Biology and later received her Doctorate of Medicine from the University of Alabama in Birmingham (UAB) in 1999. She completed a combined Internal Medicine/Pediatrics residency program at the University of Cincinnati and later completed an Endocrinology fellowship at Emory University in 2005. Dr. Smiley is currently a junior faculty member in the Division of Endocrinology and Metabolism at the Emory University School of Medicine and she recently received her Master of Science in Clinical Research degree from the Graduate School of Arts and Sciences at Emory University.
Dr. Smiley has been productive publishing manuscripts and text chapters, including the Washington Manual Type 2 Diabetes chapter, submitting scientific abstracts, obtaining grants to fund her clinical research studies, and teaching the housestaff and ancillary staff. Dr. Smiley has an NIH-KO8 award that funds her research focus in the area of ketosis-prone diabetes mellitus. She also serves as a co-investigator in several research protocols supported by the Emory University School of Medicine/Grady satellite General Clinical Research Center that concentrate on the management of inpatient hyperglycemia/insulin protocols, the effects of total parenteral nutrition in the ICU population and the effects of free fatty acids (FFAs) on endothelial function and inflammation.
Patients with ketosis-prone diabetes mellitus (KPDM) display clinical, metabolic, and immunogenetic features of type 2 diabetes during follow-up. These patients a) have markedly decreased insulin secretion and impaired insulin action, b) have a low prevalence of Beta-cell autoantibodies , and c) aggressive diabetic management results in significant improvement in Beta-cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within 3 months of follow-up. Despite this initial response, ~60% of KPDM with DKA who achieve remission relapse into hyperglycemia within 1 year if treated with diet alone. Dr. Smiley investigates patients with “KPDM” in order to correlate their response to treatment with the mechanism(s) and markers of short- and long-term remission and to determine the optimal therapeutic approach in order to prevent future glycemic decompensation.
In addition to presenting at the Endocrine division conferences, Dr. Smiley participates in the Diabetes Management Program with IM residents,the “New Directions in Diabetes” CME program which serves to educate pharmacists, diabetes educators and nurses , the EUSOM Monthly Intern Core Lecture Series and serves as the Endocrine Section Liaison for the Emory University SOM Annual Board Review Program.
Dr. Smiley has served as a a journal reviewer for peer-reviewed journals such as the Journal of Endocrinological Investigation,Diabetes, Obesity and Metabolism, Endocrine Reviews and Diabetes Care. She served as a co-chair for one of the 2008 Endocrine Society Annual Meeting abstract sessions and she is an elected Councilor for the American Federation for Medical Research (Southern Section).
- View publications on PubMed